Musk unveils SpaceX rocket designed to get to Mars and back

A prototype of SpaceX's Starship spacecraft is seen before SpaceX's Elon Musk gives an update on the company's Mars rocket Starship in Boca Chica, Texas U.S. September 28, 2019. (REUTERS)
Updated 30 September 2019

Musk unveils SpaceX rocket designed to get to Mars and back

  • A crowd watched as Musk spoke from a stage in front of the large spacecraft, which has a reflective, metal exterior

BOCA CHICA VILLAGE, Texas: Elon Musk has unveiled a SpaceX spacecraft designed to carry a crew and cargo to the moon, Mars or anywhere else in the solar system and land back on Earth perpendicularly.
In a livestreamed speech from SpaceX’s launch facility near the southern tip of Texas, Musk said Saturday that the space venture’s Starship is expected to take off for the first time in about one or two months and reach 65,000 feet (19,800 meters) before landing back on Earth.
He says it’s essential for the viability of space travel to be able to reuse spacecraft and that it’s important to take steps to extend consciousness beyond our planet.
A crowd watched as Musk spoke from a stage in front of the large spacecraft, which has a reflective, metal exterior.
Musk says Saturday marked the 11th anniversary of a SpaceX rocket reaching orbit for the first time.


GSK to produce 1 billion doses of coronavirus vaccine booster in 2021

Updated 28 May 2020

GSK to produce 1 billion doses of coronavirus vaccine booster in 2021

  • British drugmaker in talks with governments on backing for the program
  • Experts have predicted that a successful vaccine will take over a year to develop

GlaxoSmithKline will expand production of vaccine efficacy boosters, or adjuvants, to produce 1 billion doses in 2021 for use in shots for COVID-19, the British drugmaker said on Thursday.
The London-listed company said it was in talks with governments on backing for the program, which would effectively allow for a scaling up of production of future successful vaccines for the disease caused by the novel coronavirus.
GSK is one of several companies in the race to develop a vaccine for the respiratory illness that currently has no treatment and has already killed about 350,000 people.
The British drugmaker is working on its own COVID vaccine with Sanofi.
Adjuvants have been shown to create a stronger and longer-lasting immunity against infections.
GSK’s adjuvant can reduce the amount of vaccine protein required per dose, which would allow for more vaccines to be made, the British drugmaker said.
Experts have predicted that a successful vaccine will take over a year to develop, and companies and governments are pouring money into dozens of programs as the only viable solution that will allow the world to escape durably from coronavirus lockdowns and get economies moving again.